ABSTRACT
We studied 14 diabetic patients with type 2 diabetes [9 men and 5 women] in the aim to evaluate their metabolic control when treated with repaglinide while fasting during the month of Ramadan; their mean age was 50.6 +/- 2.2 year and their mean diabetes duration was 6.2 +/- 1. 3 years. We followed closely incidences of diurnal hypoglycemia and post prandial hyperglycemia. Mean glycosylated hemoglobin before Ramadan was 7.3 +/- 0.3% and none of our subjects had micro or macroangiopathy. During Ramadan, patients received repaglinide [l.l +/- 0.1mg at Iftar and 0.8 +/- 0.1mg at Shour] and metformine was continued in the 13 patients who were taking it prior to our study. Mean capillary glycemia at the end of the daily fasting was 1.32 +/- 1.06 g/l compared to 1.19 +/- 0.06 g/l for a mean fasting blood glucose before the month of Ramadan. Their mean postprandial 2H blood glucose after Iftar was 2. 15 +/- 0.17 g/l compared to 1.86 +/- 0.19 g/l for postprandial blood glucose after dinner. The mean blood glucose 2H after Shour was 1.76 +/- 0.20 g/l compared to 1.71 +/- 0.18 g/l for postprandial blood glucose after breakfast. The patients' weight remained stable; Fructosamine increased by 20.2 +/- 25.6 micro mol/l and glycosylated hemoglobin by 0.3 +/- 0.1%. Total food caloric intake and food composition remained unchanged. Only one event of clinical hypoglycemia occurred. Use of repaglinide during Ramadan decreases postprandial hyperglycemia without increasing the risk of diurnal hypoglycemia